Expanded Access to Telisotuzumab Adizutecan
NCT05982873 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-02-06
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to telisotuzumab adizutecan prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
- DRUG
-
Telisotuzumab Adizutecan
Intravenous (IV) Infusion
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
NCT01255657 ·Status: COMPLETED ·Phase: PHASE1
-
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00949910 ·Status: COMPLETED ·Phase: PHASE4
-
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00101920 ·Status: COMPLETED ·Phase: PHASE2
-
Iressa Expanded Access Program (EAP)
NCT00034879 ·Status: COMPLETED ·Phase: PHASE3
-
An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types
NCT01472003 ·Status: COMPLETED ·Phase: PHASE1
-
Medical Access Program for Patritumab Deruxtecan
NCT06099639 ·Status: NO_LONGER_AVAILABLE
-
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
NCT01931306 ·Status: APPROVED_FOR_MARKETING
-
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
NCT00988169 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT02013219 ·Status: COMPLETED ·Phase: PHASE1
-
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
NCT02883543 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
NCT00773383 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
NCT02616393 ·Status: COMPLETED ·Phase: PHASE2
-
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
NCT05798663 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00517790 ·Status: COMPLETED ·Phase: PHASE2
-
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
NCT03137264 ·Status: COMPLETED
-
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
NCT02876081 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
NCT04059887 ·Status: COMPLETED ·Phase: PHASE4
-
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
NCT02271139 ·Status: NO_LONGER_AVAILABLE
-
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
NCT06761976 ·Status: AVAILABLE
-
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
NCT02759835 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
NCT00585533 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
NCT05735327 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
NCT04294810 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03563716 ·Status: COMPLETED ·Phase: PHASE2
-
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
NCT06279728 ·Status: APPROVED_FOR_MARKETING